RRC ID 6781
著者 Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y.
タイトル Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
ジャーナル Clin Cancer Res
Abstract PURPOSE:To establish cancer immunotherapy, it is important to identify the tumor-associated antigens (TAA) that are strongly expressed in the tumor cells but not in the normal cells. In this study, to establish an effective anticancer immunotherapy, we tried to identify the useful TAA of pancreatic cancer.
EXPERIMENTAL DESIGN:Based on a previous genome-wide cDNA microarray analysis of pancreatic cancer, we focused on cadherin 3 (CDH3)/P-cadherin as a novel candidate TAA for anticancer immunotherapy. To identify the HLA-A2 (A*0201)-restricted CTL epitopes of CDH3, we used HLA-A2.1 (HHD) transgenic mice (Tgm). Furthermore, we examined the cytotoxicity against the tumor cells in vitro and in vivo of CTLs specific to CDH3 induced from HLA-A2-positive healthy donors and cancer patients.
RESULTS:CDH3 was overexpressed in the majority of pancreatic cancer and various other malignancies, including gastric and colorectal cancers, but not in their noncancerous counterparts or in many normal adult tissues. In the experiment using HLA-A2.1 Tgm, we found that the CDH3-4(655-663) (FILPVLGAV) and CDH3-7(757-765) (FIIENLKAA) peptides could induce HLA-A2-restricted CTLs in Tgm. In addition, peptides-reactive CTLs were successfully induced from peripheral blood mononuclear cells by in vitro stimulation with these two peptides in HLA-A2-positive healthy donors and cancer patients, and these CTLs exhibited cytotoxicity specific to cancer cells expressing both CDH3 and HLA-A2. Furthermore, the adoptive transfer of the CDH3-specific CTLs could inhibit the tumor growth of human cancer cells engrafted into nonobese diabetic/severe combined immunodeficiency mice.
CONCLUSIONS:These results suggest that CDH3 is a novel TAA useful for immunotherapy against a broad spectrum of cancers, including pancreatic cancer.
巻・号 14(20)
ページ 6487-95
公開日 2008-10-15
DOI 10.1158/1078-0432.CCR-08-1086
PII 14/20/6487
PMID 18927288
MeSH Adenocarcinoma / immunology Adenocarcinoma / metabolism Adenocarcinoma / therapy Adoptive Transfer Animals Cadherins / metabolism* Carcinoma, Squamous Cell / immunology Carcinoma, Squamous Cell / metabolism Carcinoma, Squamous Cell / therapy Colorectal Neoplasms / immunology Colorectal Neoplasms / metabolism Colorectal Neoplasms / therapy* Epitopes / immunology Female Gene Expression Profiling Gene Transfer Techniques HLA-A2 Antigen / physiology Humans Immunotherapy* Lentivirus Mice Mice, Inbred NOD Mice, Knockout Mice, SCID Neoplasm Proteins / genetics Neoplasm Proteins / metabolism* Oligonucleotide Array Sequence Analysis Pancreatic Neoplasms / immunology Pancreatic Neoplasms / metabolism Pancreatic Neoplasms / therapy* Peptide Fragments / immunology Peptide Fragments / metabolism RNA, Messenger / genetics RNA, Messenger / metabolism Reverse Transcriptase Polymerase Chain Reaction Stomach Neoplasms / immunology Stomach Neoplasms / metabolism Stomach Neoplasms / therapy* T-Lymphocytes, Cytotoxic / immunology Tumor Cells, Cultured
IF 10.107
引用数 67
WOS 分野 ONCOLOGY
リソース情報
遺伝子材料 CSII-CMV-RfA (RDB04386) CSII-EF-RfA (RDB04387) pCMV-VSV-G-RSV-Rev (RDB04393) pCAG-HIVgp (RDB04394)
ヒト・動物細胞 T2(RCB1932)